Cristian Seehaus

Dr. Cristian Seehaus

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 September 2023 in Hematology, Transfusion and Cell Therapy
Verified
Journal Article
Open access
CSCristian Seehaus
Cristian Seehaus
NSNatalia Schutz
Natalia Schutz
EBErika Brulc
Erika Brulc
GFGonzalo Ferini
Gonzalo Ferini
JAJorge Arbelbide
Jorge Arbelbide
ABAna Lisa Basquiera
Ana Lisa Basquiera
Introduction: The treatment of elderly multiple myeloma (MM) patients with autologous stem cell transplantation (ASCT) is a controversial procedure. Most clinical trials evaluating the safety and efficacy of ASCT have primarily included patients younger than 65 years. Design and methods This was a retrospective analysis of patients with MM who underwent ASCT between 2008 and 2018. Patients at or over 65 years were compared with patients under 65 years. We analyzed treatment-related mortality (TRM), response rate, progression-free survival (PFS) and overall survival (OS). Results: Two hundred and twenty-one patients were included: 50 patients at or over 65 years, (median age 68 years), including 7 patients over 70 years and 151 patients under 65 years, (median age 57 years). No differences were found in the neutrophil and platelet engraftment, median days of hospitalization and life support requirement during the hospitalization period for the ASCT. No statistically significant differences were found in the incidence of TRM between both groups at 100 days post-transplant (2% vs. 2.9%, p = 0.322). The ASCT improved complete response and stringent complete response rates (44% vs. 37%, p < 0.001). Survival was not modified by age: after a median follow-up of 53 months, the estimated PFS rates at three years were 63% and 60% (p = 0.88) and the OS rates at five years were 75% and 74% (p = 0.72), respectively. Conclusions: Our data suggest that the ASCT is feasible in selected elderly patients with MM over 65 years of age, achieving response and survival rates similar to those of younger patients.

8 October 2026 in Immuno
Verified
Journal Article
Open access
PDF file
MGMaria P Ghirardi
Maria P Ghirardi
PBPatricia Brandalise
Patricia Brandalise
MBMaria Ignacia Berraondo
Maria Ignacia Berraondo
CSCristian Seehaus
Cristian Seehaus
DLDANIELLE LEÃO
DANIELLE LEÃO
Ademar Dantas da Cunha JuniorAdemar Dantas da Cunha Junior
Ademar Dantas da Cunha Junior
Multiple myeloma (MM) is characterized not only by malignant plasma cell proliferation but also by progressive dysregulation of the bone marrow immune microenvironment (BMIME). Increasing evidence suggests that disease progression, therapeutic resistance, and clinical outcomes are associated with dynamic interactions between tumor cells, immune populations, stromal elements, and inflammatory signaling pathways within the marrow niche. Although many of these observations derive from high-dimensional immune profiling, spatial transcriptomics, and single-cell transcriptomic studies, emerging mechanistic and functional evidence supports an important role for immune dysregulation in shaping disease evolution, immune escape, and therapeutic responsiveness. Recent advances in spatial profiling, immune phenotyping, and multi-omic approaches have revealed profound remodeling of the immune ecosystem across the evolution from monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM) to symptomatic MM. This remodeling is characterized by progressive T-cell exhaustion, immunosenescence, dysfunction of natural killer (NK) cells, expansion of immunosuppressive myeloid populations, and altered cytokine and ligand–receptor signaling networks associated with adverse clinical outcomes. Importantly, emerging studies demonstrate that immune signatures derived from the BMIME may improve prognostic stratification beyond conventional tumor cytogenetics and staging systems. In this review, we discuss the mechanisms underlying immune dysregulation in MM, summarize recent discoveries regarding immune remodeling associated with clinical outcomes, and explore the translational implications of immune-based biomarkers and therapeutic strategies. Understanding the dynamic interplay between tumor genetics, immune-cell states, immunosenescence, and microenvironmental remodeling may facilitate the development of clinically actionable biomarkers and more personalized immunotherapeutic approaches and novel risk-adapted treatment strategies in MM.

12 September 2018
Verified
Conference Paper
Closed access
CSCristian Seehaus
Cristian Seehaus
NSNatalia Schutz
Natalia Schutz
CONTEXT: Most symptomatic multiple myeloma (MM) patients are elderly (>65 years old). Autologous stem cell transplantation (ASCT) is a standard treatment for patients under 65 years old age, whereas it is a procedure that must be individualized for elderly patients, mainly due to increase in toxicity. OBJECTIVE: To determinate effectiveness and safety of ASCT in patients older than

29 December 2025 in Current Oncology
Verified
Journal Article
Open access
PDF file
VHVania Hungria
Vania Hungria
AMAngelo Maiolino
Angelo Maiolino
RMRoberto Jose Pessoa de Magalhães
Roberto Jose Pessoa de Magalhães
NLN/A Lacerda
N/A Lacerda
GRGuillermina Remaggi
Guillermina Remaggi
BABhumika Aggarwal
Bhumika Aggarwal
As treatments for multiple myeloma (MM) evolve, there is a need for real-world insights into treatment patterns and outcomes. The treatment practices and clinical outcomes in patients with MM (TOTEMM) was a database study (2018–2024) of newly diagnosed transplant-ineligible patients with MM in Argentina (TOTEMM-A) and Brazil (TOTEMM-B) in a private healthcare setting. In TOTEMM-A (n = 72) and TOTEMM-B (n = 892), 37 and 92 different drug regimens were reported, respectively. In each country, treatment duration reduced across lines of therapy (LOT) (TOTEMM-A: range, 6.2–3.4 months; TOTEMM-B: range, 4.4–3.5 months); attrition rates increased across LOT (TOTEMM-A: range, 52.8–86.1%; TOTEMM-B: range, 41.9–88.0%); triplet regimens (mainly bortezomib based) were used most frequently in first-line (1L); >75% relapsed within 12 months, regardless of the drug prescribed; over 90% of relapses occurred between 1L and second-line, and up to half of patients were rechallenged with the same drug; >65% of patients experienced disease progression after 1L; and the 1- to 5-year adjusted cumulative risk of progression or death increased across LOT (TOTEMM-A: range, 47.1–88.5%; TOTEMM-B: range, 40.4–91.7%). The rapid and marked progression underscores the urgent need for novel treatments and regimens.